Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Taxes (2019 - 2025)

Ligand Pharmaceuticals' Current Taxes history spans 6 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Current Taxes fell 39.09% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, down 39.09%, while the annual FY2024 figure was $1.2 million, N/A changed from the prior year.
  • Current Taxes for Q3 2025 was $1.3 million at Ligand Pharmaceuticals, up from $305000.0 in the prior quarter.
  • Across five years, Current Taxes topped out at $11.4 million in Q2 2023 and bottomed at $305000.0 in Q2 2025.
  • The 4-year median for Current Taxes is $1.9 million (2024), against an average of $3.5 million.
  • The largest YoY upside for Current Taxes was 201.08% in 2023 against a maximum downside of 87.59% in 2023.
  • A 4-year view of Current Taxes shows it stood at $9.7 million in 2022, then tumbled by 87.59% to $1.2 million in 2023, then dropped by 0.42% to $1.2 million in 2024, then grew by 7.09% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Current Taxes are $1.3 million (Q3 2025), $305000.0 (Q2 2025), and $1.8 million (Q1 2025).